ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Investment analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of ImmunityBio in a research note issued on Tuesday, August 4th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.06) per share for the quarter, up from their prior forecast of ($0.07). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for ImmunityBio's current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for ImmunityBio's Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.40) EPS, FY2029 earnings at $0.94 EPS and FY2030 earnings at $1.39 EPS.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million during the quarter, compared to the consensus estimate of $49.70 million.
A number of other equities analysts have also recently commented on the stock. D. Boral Capital reissued a "buy" rating and issued a $23.00 price target on shares of ImmunityBio in a research note on Tuesday, May 5th. Weiss Ratings restated a "sell (d-)" rating on shares of ImmunityBio in a research report on Friday, July 10th. Finally, BTIG Research reaffirmed a "buy" rating and set a $12.00 price objective on shares of ImmunityBio in a report on Thursday, May 21st. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, ImmunityBio presently has a consensus rating of "Moderate Buy" and a consensus price target of $14.20.
Check Out Our Latest Stock Report on IBRX
ImmunityBio Stock Performance
Shares of IBRX stock opened at $7.25 on Thursday. The firm's 50-day simple moving average is $7.66 and its two-hundred day simple moving average is $7.64. ImmunityBio has a 52 week low of $1.95 and a 52 week high of $12.43. The firm has a market cap of $7.59 billion, a price-to-earnings ratio of -7.47 and a beta of 0.03.
Hedge Funds Weigh In On ImmunityBio
Institutional investors and hedge funds have recently made changes to their positions in the business. Western Wealth Management LLC bought a new position in shares of ImmunityBio during the first quarter valued at about $44,000. Geneos Wealth Management Inc. boosted its stake in shares of ImmunityBio by 579.3% during the first quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company's stock valued at $44,000 after purchasing an additional 4,907 shares during the period. Archer Investment Corp boosted its stake in shares of ImmunityBio by 67.1% during the first quarter. Archer Investment Corp now owns 5,872 shares of the company's stock valued at $45,000 after purchasing an additional 2,358 shares during the period. Fifth Third Bancorp grew its holdings in shares of ImmunityBio by 3,372.2% in the second quarter. Fifth Third Bancorp now owns 7,500 shares of the company's stock worth $66,000 after purchasing an additional 7,284 shares during the last quarter. Finally, Hodges Capital Management Inc. purchased a new position in shares of ImmunityBio in the first quarter worth $77,000. Institutional investors own 8.58% of the company's stock.
Insider Buying and Selling
In other ImmunityBio news, Director Cheryl Cohen sold 131,210 shares of ImmunityBio stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $9.50, for a total transaction of $1,246,495.00. Following the transaction, the director directly owned 125,386 shares of the company's stock, valued at approximately $1,191,167. This trade represents a 51.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the business's stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $7.88, for a total transaction of $197,000.00. Following the completion of the sale, the director owned 2,802,788 shares of the company's stock, valued at approximately $22,085,969.44. The trade was a 0.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 435,443 shares of company stock worth $3,918,819 in the last quarter. 66.10% of the stock is owned by insiders.
More ImmunityBio News
Here are the key news stories impacting ImmunityBio this week:
- Positive Sentiment: Record Anktiva-driven revenue growth: ImmunityBio reported second-quarter net product revenue of $50.7 million, up 92% year over year and 15% sequentially. First-half revenue reached $94.8 million, a 121% increase, indicating continued commercial adoption of Anktiva. ImmunityBio Reports Record Q2 2026 Net Product Revenue
- Positive Sentiment: Revenue exceeded expectations: Quarterly revenue of $51.24 million surpassed the $49.70 million analyst consensus, with coverage highlighting strong Anktiva uptake and additional regulatory milestones ahead. IBRX Q2 Earnings and Sales Beat Estimates
- Neutral Sentiment: Analyst outlook remains bullish but estimates are mixed: HC Wainwright reiterated its “Buy” rating and $15 price target. It raised Q3 2026 and Q4 2026 EPS forecasts slightly and increased its FY2027 estimate to $0.07, but lowered FY2026 EPS to $(0.40) from $(0.28), FY2029 to $0.94 from $0.95, and FY2030 to $1.39 from $1.41.
- Negative Sentiment: Reported earnings miss: ImmunityBio posted a quarterly loss of $(0.22) per share, well below the consensus loss estimate of $(0.08), despite beating on revenue. The earnings shortfall triggered a gap-down reaction and highlights ongoing profitability risk as the company expands commercialization. ImmunityBio Shares Gap Down After Earnings Miss
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.
Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
